A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification.
Seung-Won ChoiHyun Ae JungHee-Jin ChoTae Min KimChul-Kee ParkDo-Hyun NamSe-Hoon LeePublished in: Cancer medicine (2023)
This study did not meet the primary endpoint (PFS6); however, we found that immune signatures were significantly upregulated in the tumors with regression upon GC1118 therapy, which signifies the potential of immune-mediated antitumor efficacy of GC1118.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- gas chromatography
- open label
- cross sectional
- genome wide
- mass spectrometry
- gene expression
- randomized controlled trial
- clinical trial
- mesenchymal stem cells
- risk assessment
- double blind
- liquid chromatography
- tandem mass spectrometry
- label free
- simultaneous determination